Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab

There is little evidence regarding the maintenance of long-term clinical remission by adalimumab (ADA) therapy in Crohn's disease (CD) patients naïve to anti-tumor necrosis factor treatment (naïve CD patients), since most CD patients are treated with ADA after infliximab (IFX) therapy. The long...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizoshita, Tsutomu, Tanida, Satoshi, Ozeki, Keiji, Katano, Takahito, Shimura, Takaya, Mori, Yoshinori, Kubota, Eiji, Kataoka, Hiromi, Kamiya, Takeshi, Joh, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939671/
https://www.ncbi.nlm.nih.gov/pubmed/27462198
http://dx.doi.org/10.1159/000445105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939671/
https://www.ncbi.nlm.nih.gov/pubmed/27462198
http://dx.doi.org/10.1159/000445105

Ejemplares similares